• HPR168 Assessment of Equity in Healthcare Financing for Uganda

    Dec 1, 2023, 00:00

  • CO189 Comparative Efficacy of Voclosporin in Combination With Mycophenolate Mofetil Versus Other Treatments in Active Lupus Nephritis: Systematic Review and Network Meta-Analysis

    Dec 1, 2023, 00:00

  • HPR205 Predicting Drug Price Erosion in Germany Associated With Indication Expansion, to Understand the Potential Launch Price Benchmark for a New Product

    Dec 1, 2023, 00:00

  • EE355 Pre-Progression Health State Utility Values From the TALAPRO-2 Clinical Trial in Patients With Metastatic Castration-Resistant Prostate Cancer With HRR Mutations

    Dec 1, 2023, 00:00

  • PT15 Comparing the Impact of Random Forest Vs Bayesian G-Computation on Matching-Adjusted Indirect Comparisons of Treatments Between Trials: A Simulation Study

    Dec 1, 2023, 00:00

  • HSD106 Analysis of Health Economic Evidence in Clinical Practice Guidelines Published in China Between 2017 and 2022: An Investigative Study

    Dec 1, 2023, 00:00

  • HSD11 Hospital Capacity Tool to Assess the Potential Impact of Using a Fixed Dose Combination of Pertuzumab/Trastuzumab for Subcutaneous Injection Versus Intravenous Pertuzumab/Trastuzumab in HER2+ Breast Cancer

    Dec 1, 2023, 00:00

  • MSR139 Performance of Different Survival Models for Extrapolation of Immature OS Data for 2L+ NSCLC Therapies

    Dec 1, 2023, 00:00

  • HPR84 Impact of AIFA Monitoring Registries Closure on Drugs’ Turnover Trends in Italy

    Dec 1, 2023, 00:00

  • HTA125 Assessment Outcome by HTA Agency Archetype: Five-Year Review for 20 European Countries

    Dec 1, 2023, 00:00

  • MSR117 Identifying Economic Insecurity Among Psoriasis Patients Using Natural Language Processing and Unstructured Clinical Notes

    Dec 1, 2023, 00:00

  • EPH213 Hepatitis B Virus (HBV) and Human Papilloma Virus (HPV) Related Cancers Elimination Impact on Treatment Patterns (HELP-France) in France

    Dec 1, 2023, 00:00

  • HSD74 Cost Savings as a Result of Biosimilar Medications Adoption in One of the Tertiary Governmental Hospitals in Riyadh, Saudi Arabia.

    Dec 1, 2023, 00:00

  • HTA296 Applying Continual Stakeholder Engagement to Develop Multi-Criteria Decision Analysis (MCDA) for Health Technology Assessment in Major Depressive Disorder (MDD)

    Dec 1, 2023, 00:00

  • HSD59 Exploring Factors for Regional Differences in Inappropriate Psychotropic Drug Prescribing: Ecological Study Using a Claims Database in Japan

    Dec 1, 2023, 00:00

  • MT17 Cost and Resource Use Outcomes for Left Atrial Appendage Occlusion Patients Contraindicated to Transesophageal Echocardiography

    Dec 1, 2023, 00:00

  • EE539 The Economic Burden of Systemic Drug Therapy Administration Route in Treating HER2-Positive Breast Cancer for Patients, Healthcare Professionals, and Healthcare System: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • CO129 Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy (RWPC) for Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

    Dec 1, 2023, 00:00

  • HPR95 Public-Private Partnership Model in Oncology: Business Opportunities for Next Generation Contract Research Organizations in the Context of CancerX

    Dec 1, 2023, 00:00

  • MT2 Description of Portal Hypertension Treatment by Transjugular Intrahepatic Portosystemic Shunt: A French National Hospital Database Analysis

    Dec 1, 2023, 00:00

  • EE576 Costs Saving Generated by Anti-TNF Biosimilars Market Penetration in Fran An Analysis Based on French Health Insurance Open Data

    Dec 1, 2023, 00:00

  • SA69 Impact of COVID-19 on Health Care Resource Utilization and Costs in Patients With Chronic Obstructive Pulmonary Disease and Asthma in the United States (2018–2022): A Population-Based Study

    Dec 1, 2023, 00:00

  • HTA238 Oncological Combination Therapies in the Context of the Early Benefit Assessment According to AMNOG: Status Quo and Quo Vadis

    Dec 1, 2023, 00:00

  • HPR199 To Operationalize the VBHC in the Medical Device Area – An Italian Experience

    Dec 1, 2023, 00:00

  • EPH83 Ecological Study of the Incidence and Prevalence of Cancer Associated with Social Determinants of Health

    Dec 1, 2023, 00:00

  • EE313 Cost-Utility of Apixaban for Secondary Stroke Prevention in Brazil

    Dec 1, 2023, 00:00

  • SA39 Targeted Treatments for Patients with Relapsed and/or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): A Systematic Literature Review (SLR) of Randomized Clinical Trials (RCTs)

    Dec 1, 2023, 00:00

  • EE197 Cost-Effectiveness Analysis of Spinal Cord Stimulation in Sweden

    Dec 1, 2023, 00:00

  • MT57 Optimization of Patient Scheduling Based on AI Algorithm of the Radiotherapy Department of Liège University Hospital: Presentation of Selected Key Performance Indicators (KPIs) (HosmartAI - Horizon 2020 Funded)

    Dec 1, 2023, 00:00

  • RWD160 Time to Treatment Initiation and Patient Characteristics in Newly Diagnosed Multiple Myeloma Patients With and Without Transplant: Real-World Evidence Using Big Data From England

    Dec 1, 2023, 00:00

  • EPH86 Access to a First Disease-Modifying Therapy Leads to a Disproportionate Increase in the Patient Population Diagnosed with a Rare Disease

    Dec 1, 2023, 00:00

  • EE310 Botulinum Toxin Type a for the Treatment of Patients with Post-Stroke Focal Spasticity in Thailand: A Cost-Utility Analysis

    Dec 1, 2023, 00:00

  • PCR136 The Burden of Systemic Mastocytosis in Select European Countries: Evidence from the Prism Patient Survey

    Dec 1, 2023, 00:00

  • HTA305 Multicriteria Decision Analysis (MCDA) to Elicit Criteria for CAR-T Cell Health Technology Assessment (HTA) in Brazilian Private Healthcare System

    Dec 1, 2023, 00:00

  • PCR103 Validating an Herpes Zoster Health Related Quality of Life Conceptual Model in Argentina: Literature Review and Qualitative Study

    Dec 1, 2023, 00:00

  • EE304 Estimating Health Related Quality of Life Effects in Vitiligo: Mapping EQ-5D-5L Utilities from Vitiligo Specific Scales, Re-Pigmentation Measures Using Data from the HI-Light Trial

    Dec 1, 2023, 00:00

  • HTA161 Can We Elicit a Willingness to Pay Threshold for Oncology Treatments in Denmark?

    Dec 1, 2023, 00:00

  • HPR159 Emerging Trends Shaping the Healthcare Ecosystem in the Middle East and North Africa Region

    Dec 1, 2023, 00:00

  • PT36 Real-World Analysis on Therapeutic Pattern and Economic Burden of Androgen-Receptor Signaling Inhibitors (ARSI) and Taxane-Based Chemotherapy Treated Metastatic Castration-Resistant Prostate Cancer Patients in Italy

    Dec 1, 2023, 00:00

  • EE117 Cost-Effectiveness of Empagliflozin in Patients Affected By Chronic Kidney Disease in Italy

    Dec 1, 2023, 00:00

  • HTA276 Comparison of Health Technology Assessment Systems: A Review of Their Impact on Expenditure and Outcomes

    Dec 1, 2023, 00:00

  • EE706 Impact of Valoctocogene Roxaparvovec on the Economic Burden of Adults with Severe Hemophilia A Managed with Prophylaxis in the United States

    Dec 1, 2023, 00:00

  • HTA113 How Have Manufacturers Maximised Their Digital Health Technologies’ Chances of Successful Reimbursement in Germany?

    Dec 1, 2023, 00:00

  • PCR231 The Socio-Economic Burden on Caregivers of Pediatric Autistic Population in Europe: A Systematic Review

    Dec 1, 2023, 00:00

  • HSD8 Enhancing Prostate Cancer Care by Optimizing Patient Engagement with Digital Tools

    Dec 1, 2023, 00:00

  • CO40 Non-Communicable Diseases Prevention in India: A Review of Suitable Instruments for Surveillance and a General Overview of Cultural, Behavioral Practices and Risk Factors for the Adult Population

    Dec 1, 2023, 00:00

  • SA45 Natural Evolution of Chronic Kidney Disease in Diabetic Patients: Costs and Consequences in Portuguese Reality

    Dec 1, 2023, 00:00

  • MSR58 It's Alive! Feasibility and Benefits of Living Cost-Effectiveness Modeling Following a Living SLR

    Dec 1, 2023, 00:00

  • PCR77 Symptom Burden and Health-Related Quality of Life (HRQoL) in Gastrointestinal (GI) Cancers: A Targeted Literature Review

    Dec 1, 2023, 00:00

  • EE641 Socioeconomic Status and Economic Burden of Pertussis in Adults: Post-Hoc Analyses of a Retrospective Database Study in England

    Dec 1, 2023, 00:00

  • EE556 Beclometasone/Formoterol/Glycopyrronium Vs. Fixed and Open Combinations of Inhaled Corticosteroids, Long-Acting B2-Agonist, and Long-Acting Muscarinic Antagonist in Adults with Uncontrolled Asthma: A Network Meta-Analysis

    Dec 1, 2023, 00:00

  • CO30 Disease Burden and Efficacy of Current Treatment for Non-Neuronopathic MPS II Patients: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • EE330 Economic Burden of Biologic Therapy for Chinese Patients with Crohn's Disease

    Dec 1, 2023, 00:00

  • HTA96 Carer Burden: Is HTA Helping or Harming the Gender Health Gap?

    Dec 1, 2023, 00:00

  • The Health Inequality Impact of Liquid Biopsy to Inform First-Line Treatment of Advanced Non–Small Cell Lung Cancer: A Distributional Cost-Effectiveness Analysis

    Dec 1, 2023, 00:00

  • EE235 Economic Evaluations of Medical Devices Used in the Treatment of Breast Cancer: A Systematic Review

    Dec 1, 2023, 00:00

  • RWD128 The Burden of Illness in Duchenne Muscular Dystrophy: Evidence Gaps and Research Needs

    Dec 1, 2023, 00:00

  • HTA28 The Use of Expert Opinions, Patient, and Carer Perspectives and Real-World Evidence in Orphan Disease Submissions Differs for Health Technology Assessment Agencies Across the World

    Dec 1, 2023, 00:00

  • EE119 Development of a De Novo Model to Assess the Cost-Effectiveness of a New Treatment Option for Patients With Primary Immunoglobulin a Nephropathy (IgAN)

    Dec 1, 2023, 00:00

  • The Role of Artificial Intelligen From Economic Modelling to Clinical Decision Making

    Dec 1, 2023, 00:00

  • MT34 Adaptation and Cost-Effectiveness Analysis of the "My Health Everyday” Medication Adherence Coaching Application for Hypertension Management in Hungary

    Dec 1, 2023, 00:00

  • MT38 Identifying High Cost and High Mortality Genetic Disease in the NICU

    Dec 1, 2023, 00:00

  • EE349 The Impact of Using Real-World Data on the Cost-Effectiveness of Fremanezumab for Migraine Prevention in a UK Healthcare Perspective Analysis

    Dec 1, 2023, 00:00

  • EE54 Costs of Proton Radiotherapy and Photon Radiotherapy for Non-Small Cell Lung Cancer in the Netherlands Using a Time-Driven Activity-Based Costing Approach

    Dec 1, 2023, 00:00

  • EE129 Health-Economic Analysis of Digestive Stents in France Based on the French Social Insurance Healthcare Database

    Dec 1, 2023, 00:00

  • HTA126 How Did French Health Technology Assessment Body (Transparency Committee, TC, of the HAS) Assess Drugs with Clinical Development Based on Single Arm Trials in the Last Three Years?

    Dec 1, 2023, 00:00

  • EE34 Cost-Effectiveness Analysis of Aztreonam-Avibactam (ATM-AVI) Versus Meropenem for the Treatment of Serious Infections Due to Gram-Negative Bacteria for Which There Are Limited Treatment Options (LTO) in Italy

    Dec 1, 2023, 00:00

  • PCR91 Patients’ Needs in Assessing Long COVID: A Review of Relevant Concepts and Patient-Reported Outcomes

    Dec 1, 2023, 00:00

  • Impact of Regulatory Affairs on Access

    Dec 1, 2023, 00:00

  • EPH189 Factors Associated with Biosimilar Prescription for Anti-Cancer Biologics Among 58,915 Patients in Europe

    Dec 1, 2023, 00:00

  • OP16 Environmental Sustainability Success Stories From the Pharmaceutical and Medtech Industries in Europe: A Targeted Literature Review

    Dec 1, 2023, 00:00

  • HTA326 Indication-Based Pricing of the Pharmaceuticals in Croatia: Case-Study Modelling Excercise

    Dec 1, 2023, 00:00

  • EE108 Cost-Effectiveness Analysis of Abrocitinib Versus Dupilumab for Treatment of Moderate-to-Severe Atopic Dermatitis in Chinese Adults

    Dec 1, 2023, 00:00

  • HTA34 Demonstrating Similar or Greater Health Benefits Based on Indirect Eviden A Review of NICE Evaluations That Include a Cost-Comparison Approach

    Dec 1, 2023, 00:00

  • SA77 Health Technology Assessment (HTA) Feasibility Study: The XprESS Device for the Treatment of Patients With Eustachian Tube Dysfunction

    Dec 1, 2023, 00:00

  • Differences and New Developments in HTA Around the World

    Dec 1, 2023, 00:00

  • HPR64 Lack of Incentives, Lack of Sanctions, Lack of Complian Early Notification of Impending Drug Shortages in Eight European Countries

    Dec 1, 2023, 00:00

  • EE478 Obesity-Related Outcomes and Cost Impact of Weight Loss in Saudi Arabian Privately Insured Adults

    Dec 1, 2023, 00:00

  • CO194 Integration of Clinical Outcome Assessments (COA) in Drug Approval Process to Foster Patient-Centric Clinical Trials: A Review of 3 Regulatory Guidelines for Drug Development in the APAC

    Dec 1, 2023, 00:00

  • PCR141 The Impact of Duchenne Muscular Dystrophy on Caregiver Employment: A Survey in Europe, Japan, and the United States

    Dec 1, 2023, 00:00

  • MSR160 Screening Tools for Streamlining Systematic Literature Review Process: Reviewers' Perspective

    Dec 1, 2023, 00:00

  • EE670 Management Costs of Grade 3/4 Adverse Events Associated with Emerging and Existing Systemic Therapies for Metastatic Colorectal Cancer with at Least Two Prior Lines of Therapy in Italy, Portugal, Spain, and the United States

    Dec 1, 2023, 00:00

  • EE312 Multi-Comparator ICERS in Cost-Effectiveness Analysis to Account for Changes in Clinical Practice after the Introduction of a New Technology

    Dec 1, 2023, 00:00

  • HSD9 Access to Precision Medicine in Mexico: Differences of Therapy Patterns for ALK+ and EGFR+ Non-Small Cell Lung Cancer (NSCLC) Patients

    Dec 1, 2023, 00:00

  • EE195 Quantifying the Avoided Costs of a Switch to Ofatumumab From Low/Moderate Efficacy Disease Modifying Therapies in Patients With Relapsing-Remitting Multiple Sclerosis in Colombia

    Dec 1, 2023, 00:00

  • EE220 Cost-Effectiveness Analysis of Netupitant/Palonosetron for Chemotherapy Induced Nausea and Vomiting in Brazilian Private Healthcare System Perspective

    Dec 1, 2023, 00:00

  • EE550 Lifetime Cost of Orphan Therapies in Paediatric Indications in Europe

    Dec 1, 2023, 00:00

  • HPR51 Better Safe Than Sorry? Identification of Drug Combinations for Targeted Price Regulation in German Claims Data

    Dec 1, 2023, 00:00

  • MSR31 A Simulation Study to Examine the Influence of Varied Standard Deviation of Covariates across Trials on Population Adjusted Indirect Treatment Comparisons

    Dec 1, 2023, 00:00

  • CO103 Modelled Impact of Nirsevimab for All Infants in Preventing Respiratory Syncytial Virus (RSV): Related Hospitalizations and Costs in the Brazilian Private Healthcare System

    Dec 1, 2023, 00:00

  • P28 Medication Non-Adherence in Patients with Varying Levels of Depression Symptoms Measured Using the Medication Adherence Reasons Scale

    Dec 1, 2023, 00:00

  • HTA45 Study of HTA Timelines and Outcomes for MHRA-Approved NASs in the Post-Brexit UK via Reliance/Work-Sharing Routes

    Dec 1, 2023, 00:00

  • HTA175 The Impact of Accelerated Regulatory Approval on Health Technology Assessment: An Evaluation of Orphan Drugs in Four Markets

    Dec 1, 2023, 00:00

  • Innovations in Modeling for Health Technology Assessment

    Dec 1, 2023, 00:00

  • HPR181 Comprehensive and Standardized Value Assessment of Innovative Cancer Treatments: A Multi-Criteria Decision Analysis (MCDA) Tool for Switzerland

    Dec 1, 2023, 00:00

  • EE663 The Disease and Economic Burden of Hepatocellular Carcinoma in Australia

    Dec 1, 2023, 00:00

  • EE695 Cost-Effectiveness of a New Multi-Lumen Infusion Device to Reduce Central Venous Line-Related Infections in a Neonatal Intensive Care Unit

    Dec 1, 2023, 00:00

  • EPH253 Epidemiology Disease Burden of Polycistic Ovary Syndrome Based on Routinely Collected Health Insurence Claims Data Between 2010-2019

    Dec 1, 2023, 00:00

  • Disclaimer

    Dec 1, 2023, 00:00

  • EE260 Cost-Effectiveness Analysis of Daratumumab Triplet Therapy Vs Carfilzomib Duplet Therapy in Patients with Relapsed or Refractory Multiple Myeloma in Egypt from Payer Perspective

    Dec 1, 2023, 00:00

  • HTA72 How Is Real-World Evidence (RWE) Being Used in Health Technology Assessment (HTA) Decisions? Qualitative Insights from Comparisons of Three RWE Study Types Across Multiple Jurisdictions

    Dec 1, 2023, 00:00

  • Advancements in Digital Health Interventions: Evidence Syntheses, Value Assessment, and Global Perspectives

    Dec 1, 2023, 00:00

  • EPH183 The Effects of COVID-19 on Mental Health

    Dec 1, 2023, 00:00

  • HPR170 Time to Reimbursement in Ireland; Utilizing Regression Analysis to Assess Factors Contributing to Overall Timelines

    Dec 1, 2023, 00:00

  • HTA32 When Should the Conduct of RWE Studies Be Prioritized for Reimbursement: Insights from Canadian and Global Stakeholders

    Dec 1, 2023, 00:00

  • RWD4 Socioeconomic Burden of Obesity – Increased Rate and Duration of Sick Leave in Patients Living with Obesity: A Cross-Sectional Claims Data Analysis in Germany

    Dec 1, 2023, 00:00

  • SA62 A Methodological Approach for the Design of a Unique Post Market Clinical Follow-up Study for Standard and Custom-Made Devices According to EU Medical Device Regulation 2017/745

    Dec 1, 2023, 00:00

  • HTA10 Exploring the Impact of End-of-Life Designation on Access to Oncology Therapies in the United Kingdom

    Dec 1, 2023, 00:00

  • EPH23 Diagnosis Patterns in Breast Cancer Women in Brazil: Inequities Among Public and Private Settings in São Paulo State

    Dec 1, 2023, 00:00

  • PCR96 Long Term Consequences of COVID-19 in Quality of Life in Patients Discharged From Hospital: Systematic Review

    Dec 1, 2023, 00:00

  • EE153 Using a Cumulative Low-Density Lipoprotein Cholesterol Modelling Approach to Estimate the Reduction of Risk of Atherosclerotic Cardiovascular Events from a Primary Prevention Program

    Dec 1, 2023, 00:00

  • MT58 Implications of VivaSight-DL: Procedural Impact of a Camera-Integrated Double Lumen Tube

    Dec 1, 2023, 00:00

  • MSR116 Unsupervised Clustering and Binary Classification Analysis for Predicting Long COVID Among Adults in EU4 and UK

    Dec 1, 2023, 00:00

  • EE398 Economic Burden of Wilson's Disease: A Systematic Review

    Dec 1, 2023, 00:00

  • PCR184 A Systematic Literature Review of Patient-Reported Outcomes With Nivolumab Across Lung Cancers

    Dec 1, 2023, 00:00

  • EPH188 Social Determinants of Health and Treatment Receipt Among Privately and Publicly Insured Adults Diagnosed With Cancer in the United States

    Dec 1, 2023, 00:00

  • EPH214 Estimating the Burden of Vaccine-Preventable Insect-Borne Diseases Without Vaccination Alternatives in Europe: What's Going on in Spain and Germany?

    Dec 1, 2023, 00:00

  • RWD81 Annual Nationwide Epidemiological and Health Insurance Burden of Hip Osteoarthritis in Hungary: A Burden of Disease Study Based on Real World Data

    Dec 1, 2023, 00:00

  • PT44 Cost-Effectiveness of Olaparib Vs. Rucaparib for Patients with Metastatic Castration-Resistant Prostate Cancer – the Canadian Perspective

    Dec 1, 2023, 00:00

  • EE399 Exploring the Economic Consequences of Caring for Patients With Rare Diseases: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • HPR146 Fit for Purpose Policy Recommendations Related to Funding, Pricing, and Procurement of Point-of-Care Tests Used in Patients With Respiratory Tract Infections

    Dec 1, 2023, 00:00

  • EE495 Cost of Spinal Muscular Atrophy(SMA) Management in Turkiye

    Dec 1, 2023, 00:00

  • P11 Real-World Evidence of Total Colonoscopy for Colorectal Cancer Screening Based on Test Performance RCTs

    Dec 1, 2023, 00:00

  • EPH211 The Public Health Impact of mRNA-1273 Fall Booster Vaccination in the Netherlands

    Dec 1, 2023, 00:00

  • MSR5 Accuracy of Automated Data Extraction for Systematic Literature Reviews

    Dec 1, 2023, 00:00

  • MSR100 Exploring Methods to Include Carbon Footprint into an HTA: The Case of Remote Patient Management

    Dec 1, 2023, 00:00

  • PCR47 Consumer Preferences for Attributes of Influenza Vaccines in the United States: Results from a Discrete-Choice Experiment Study

    Dec 1, 2023, 00:00

  • EE410 Retrospective Database Analysis of Healthcare Resource Utilization and Costs in Patients With Vitiligo in Quebec, Canada

    Dec 1, 2023, 00:00

  • SA73 A Retrospective Cohort Study to Evaluate the Disease Burden, Treatment Patterns, Healthcare Resource Utilization, and Costs in Patients with Breast Cancer in Dubai, United Arab Emirates

    Dec 1, 2023, 00:00

  • OP17 Mapping Pharma Market Access Executives in Greece

    Dec 1, 2023, 00:00

  • EE479 The Cost of Treating Gastroesophageal Reflux Disease: A Systematic Review

    Dec 1, 2023, 00:00

  • EPH15 Transmission Dynamics and Vaccination Strategies for Chikungunya Virus (CHIKV): An Outbreak Simulation Study in Rome, Italy

    Dec 1, 2023, 00:00

  • EE300 Looking Sharp! Applying Cutting-Edge Shapley Additive Explanation (SHAP) Approaches to Cost-Effectiveness Modelling in Contrast to One-Way Sensitivity Analysis

    Dec 1, 2023, 00:00

  • EE488 Budget Impact Analysis of Oral Treatment With Nirmaltrevir+Ritonavir for COVID-19 in Argentina

    Dec 1, 2023, 00:00

  • OP6 Overcrowding and Boarding Time: Emergency Department Performance and Impacting Factors

    Dec 1, 2023, 00:00

  • RWD16 Identifying Oncology Effectiveness Endpoints Using Administrative Secondary Databases: An Example Utilising Hospital Episode Statistics in England

    Dec 1, 2023, 00:00

  • Real-World Cost-Effectiveness of Pulmonary Vein Isolation for Atrial Fibrillation: A Target Trial Approach

    Dec 1, 2023, 00:00

  • Has the Centers for Medicare Medicaid Services Implicitly Adopted a Value Framework for Medicare Drug Price Negotiations? [Editor's Choice]

    Dec 1, 2023, 00:00

  • HTA129 Learnings from TC Opinions of Drugs Evaluated for EAP Under New Process

    Dec 1, 2023, 00:00

  • PCR221 Real-World Adherence to Anti-PCSK9 Monoclonal Antibody (mAb) and Its Impact on Economic Burden of Cardiovascular Diseases in Patients with Hypercholesterolemia: A Retrospective Cohort Study in China

    Dec 1, 2023, 00:00

  • PCR24 Patient and Caregiver Perceptions of Systemic Anticancer Treatments in Advanced Bladder Cancer (aBC): Results of a Social Media Listening (SML) Study Conducted in 5 European Countries (Eu5)

    Dec 1, 2023, 00:00

  • HTA180 Analyzing Transparency Committee Discussions: A Database Approach to Understanding Decision-Making Factors

    Dec 1, 2023, 00:00

  • HTA215 Utilization of RWE in HTA Appraisals in England, Scotland, Germany, and France

    Dec 1, 2023, 00:00

  • EPH235 The Road to an HIV Cure: Approaches and Strategies in Current Clinical Trials

    Dec 1, 2023, 00:00

  • EPH130 Drug Utilization Patterns of Guanfacine Hydrochloride Indicated for Attention Deficit Hyperactivity Disorder in European Countries

    Dec 1, 2023, 00:00

  • HTA103 Systematic Literature Reviews to Identify Clinical and Economic Outcomes in Adults With Pompe Disease

    Dec 1, 2023, 00:00

  • EE461 An Italian Real-World Analysis of Economic Impact in Patients with Hypercholesterolemia Treated with Rosuvastatin/Ezetimibe as Free Vs Single-Pill Combination

    Dec 1, 2023, 00:00

  • EE740 Costs and Clinical Outcomes of Colorectal Cancer Surgeries: Results From the Emilia-Romagna Surgical Colorectal Audit (ESCA)

    Dec 1, 2023, 00:00

  • HTA242 Incorporating Health Inequalities (HIs) Considerations into United Kingdom (UK) HTA Decision Making and the Impact on Rare Disease Medicines

    Dec 1, 2023, 00:00

  • PT3 Concept Elicitation Interviews to Refine a Conceptual Model of the Patient Experience of Amyotrophic Lateral Sclerosis (ALS)

    Dec 1, 2023, 00:00

  • EE534 Economic Burden of Waldenström Macroglobulinemia, Marginal Zone Lymphoma and Chronic Lymphoid Leukemia

    Dec 1, 2023, 00:00

  • EE417 Budget Impact of Efmoroctocog Alfa in Treatment of Severe Haemophilia a Patients in Turkey

    Dec 1, 2023, 00:00

  • EE430 Use of Single-Arm Trials in Health Technology Assessment Reviews of Axicabtagene Ciloleucel

    Dec 1, 2023, 00:00

  • PCR128 A Systematic Literature Review of Patient-Reported Outcomes With Nivolumab Across Gastric and Oesophageal Cancers

    Dec 1, 2023, 00:00

  • HTA317 Comparing Ultra-Rare Disease Pathways Within the United Kingdom: Can Different Processes Lead to Market Access Variations?

    Dec 1, 2023, 00:00

  • HTA254 Potential Discrepancies/Misalignments in Future EU-HTA Appraisals the POLIVY and Stelara JA3 PICO Example

    Dec 1, 2023, 00:00

  • EE333 Cost-Effectiveness of Once-Weekly Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in the UK

    Dec 1, 2023, 00:00

  • EE437 Cost-Utility Analysis of Acupotomy with Nerve Block Therapy from Lumbosacral Radiculopathy Patients in Korea

    Dec 1, 2023, 00:00

  • HPR32 Is NRDL Supporting Access or Hindering Access in China? A Time-Trend Analysis From 2017-2022

    Dec 1, 2023, 00:00

  • EE392 The Potential Impact of Delandistrogene Moxeparvovec on Work Productivity on Individuals With Duchenne Muscular Dystrophy in the United States (US)

    Dec 1, 2023, 00:00

  • HTA277 Requirements for Clinical Evidence for Health Technology Assessment Submissions Across Different Countries

    Dec 1, 2023, 00:00

  • MSR113 Inferring the Proportion of Durable Responders to Targeted Oncology Therapies in Combination Regimens Using Bayesian Parametric Mixture Survival Models

    Dec 1, 2023, 00:00

  • EE386 Budget Impact of Durvalumab for the Treatment of Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Brazilian Private Healthcare System

    Dec 1, 2023, 00:00

  • HPR111 ATMPs in Europe: Do We Have an Access Gap?

    Dec 1, 2023, 00:00

  • EE65 Evaluating the Cost-Effectiveness of Next-Generation Sequencing as a Biomarker Testing Strategy in Oncology and Implications for Policy: A Literature Review

    Dec 1, 2023, 00:00

  • MSR114 Reducing Mortality From Malignant Neoplasms: The Promising Role of Modern Antineoplastic Drugs in Lung Cancer Treatment

    Dec 1, 2023, 00:00

  • MSR163 Artificial Intelligence (AI)-Based Screening: Exploration of Differences in Two Health Technology Assessment (HTA)-Compliant Systematic Literature Reviews (SLRS)

    Dec 1, 2023, 00:00

  • HTA142 Evolution of French Economic Opinions Published by the Economic Evaluation and Public Health Committee (CEESP)

    Dec 1, 2023, 00:00

  • MSR50 Comparing Treatment Options for Fabry Disease: Feasibility Assessment for Network Meta-Analysis (NMA)

    Dec 1, 2023, 00:00

  • RWD55 Retrospective Observational Study of Real-World Treatment Patterns and Financial Burden in Patients With Premenopausal Metastatic HR+/HER2- Breast Cancer

    Dec 1, 2023, 00:00

  • HPR177 Overview of Reimbursement Criteria for Bariatric Surgery in 23 Countries

    Dec 1, 2023, 00:00

  • EPH266 Mechanisms of HPV Vaccine Knowledge Levels Under Restricted Supply of Nine-Valent Vaccine in China Mainland

    Dec 1, 2023, 00:00

  • PCR113 EQ-5D Studies in Pediaric Diabetes: A Systematic Review

    Dec 1, 2023, 00:00

  • SA61 Economic Burden of Patients in the United States with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A Focused Literature Review

    Dec 1, 2023, 00:00

  • HPR186 Implementation of Risk-Sharing Agreement in Patients with Lung Cancer Treated with Immunotherapy Based on RWD in the Czech Republic

    Dec 1, 2023, 00:00

  • HTA283 A Scoping Review of Health Technology Assessment Agency (HTA) and Health Economic (HE) Modelling Guidelines for Identification of Health Economic Model Inputs

    Dec 1, 2023, 00:00

  • EE412 Unraveling the Disease Burden of Generalized Pustular Psoriasis: A Comparative Analysis of Flares with Psoriasis Vulgaris in Taiwan

    Dec 1, 2023, 00:00

  • MT5 Mapping Facilities, Equipment and Trained Personnel of Radiotherapy in Greece

    Dec 1, 2023, 00:00

  • EE61 Relationship between Health-Related Quality of Life and Productivity Loss and Indirect Costs of Leukemia and Lymphoma Patients and Caregivers: Estimates from a Cross-Sectional Study from Portugal

    Dec 1, 2023, 00:00

  • EE371 Economic Evaluation of Anaplastic Lymphoma Kinase (ALK) Inhibitors Compared with Standard Chemotherapy in Thailand

    Dec 1, 2023, 00:00

  • EE53 An Investigation of Value for Money of Oncology Drugs in Canada

    Dec 1, 2023, 00:00

  • PCR143 European Quality of Life Five Dimension (EQ-5D) Utility Values for Clinical Health States in Fabry Disease (FD): Insights from Pegunigalsidase Alpha Clinical Trials

    Dec 1, 2023, 00:00

  • EE600 Prediction of Price Dynamics of Medicine in the Netherlands

    Dec 1, 2023, 00:00

  • MSR9 Adjusting for Switches to Multiple Treatments in Randomised Controlled Trials: A Comparison of Inverse Probability Weighting and Two-Stage Estimation Methods

    Dec 1, 2023, 00:00

  • EE307 Drive-the-Doctor Paradigm for Acute Ischemic Stroke with Large Vessel Occlusion: A Cost-Effectiveness Analysis

    Dec 1, 2023, 00:00

  • MSR21 Methodological Aspects of a COVID-19 Vaccine Discrete Choice Experiment Survey in Canada, Germany, UK, and US General Populations

    Dec 1, 2023, 00:00

  • HTA187 Advancing a Collaborative Value Assessment Framework for Next-Generation Sequencing/Comprehensive Genomic Profiling in Europe: Building on and Enhancing an Existing Framework – A Multi-Stakeholder Web-Delphi Approach

    Dec 1, 2023, 00:00

  • EE552 Healthcare Resource Utilization in Alpha-Mannosidosis: Results from an International Caregiver Survey

    Dec 1, 2023, 00:00

  • HSD79 Assessment of Patient Satisfaction with Public Pharmacies Dispensing High-Cost Drugs in Greece

    Dec 1, 2023, 00:00

  • RWD144 Coded Diagnoses Versus Proxy-Based Diagnoses in Primary Care: Registration By General Practitioners in the PHARMO GP Data

    Dec 1, 2023, 00:00

  • PCR70 Factors Associated with Taking Preventive Migraine Medicines: Results from Overcome (EU) Study

    Dec 1, 2023, 00:00

  • PCR40 Unmet Medical Needs and Treatment Preferences for Systemic Treatments in Patients with Moderate to Severe Psoriasis: A Cross-Sectional Survey Study in China

    Dec 1, 2023, 00:00

  • HPR145 Access of Rare Disease Treatments in the Nordics

    Dec 1, 2023, 00:00

  • EE446 Cost-Effectiveness Analysis of Nuvaxovid Vaccination for Japanese Elderly Population

    Dec 1, 2023, 00:00

  • EE241 Budget Impact of Making Emicizumab Available at the Community Pharmacy in Addition to the Hospital Pharmacy

    Dec 1, 2023, 00:00

  • HPR14 Applications for Tafamidis (Vyndaqel®) Under a Managed Access Protcol in Ireland

    Dec 1, 2023, 00:00

  • EE504 Buprenorphine–Naloxone Film Yields Cost Savings in Administration Time Compared With Sublingual Tablets in Sweden

    Dec 1, 2023, 00:00

  • EPH98 Real-World Effectiveness and Safety of Tixagevimab-Cilgavimab: A Target Trial Emulation Study

    Dec 1, 2023, 00:00

  • CO134 Estimating the Direct and Indirect Resource Burden of Treatment Management with Current Standard of Care or Elacestrant for ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer Patients: A Population-Level Provider Model

    Dec 1, 2023, 00:00

  • HTA252 Shorter Time to Market for Pharmaceuticals Assessed in the Nordic HTA-Collaboration FINOSE

    Dec 1, 2023, 00:00

  • MT39 Development of an Early Economic Model to Assess the Cost-Effectiveness of a Novel Technology for the Treatment and/or Prevention of Cataracts

    Dec 1, 2023, 00:00

  • EE209 Can the German Efficiency Frontier Approach Support Decision-Making Processes for Pricing New Medicines? An Application to Second-Line Interventions of Transplant-Ineligible Diffuse Large B-Cell Lymphoma

    Dec 1, 2023, 00:00

  • MSR36 Model Framework to Derive Prevalence Estimates of Hepatitis Delta Based on Migration Patterns

    Dec 1, 2023, 00:00

  • HSD93 Towards Diagnosing Rare Diseases: Referral Behavior of Physicians in Europe

    Dec 1, 2023, 00:00

  • PCR56 Is Walking As Important As Muscle Strength After Stroke? Preference Weighting of ICF's Core Elements

    Dec 1, 2023, 00:00

  • RWD137 Real-World Osteoporosis Drug Utilization in Patients with Recurrent Osteoporotic Fracture: A Nationwide Cohort Study in South Korea

    Dec 1, 2023, 00:00

  • EE215 Estimation of 10-Year Healthcare Costs of Patients Diagnosed With Myeloproliferative Neoplasms in Denmark

    Dec 1, 2023, 00:00

  • SA26 Prevalence and Burden of Lupus in Adult French Population: A Retrospective Longitudinal National Hospital Claims Study

    Dec 1, 2023, 00:00

  • EE674 Healthcare Resource Use and Costs Associated with Endometrial Cancer Treatment in the Private Setting in Brazil

    Dec 1, 2023, 00:00

  • HTA297 The Inclusion of Caregiver Burden in the National Institute for Health and Care Excellence (NICE) Health Technology Appraisals (HTAS) of Treatments for Mental Health Disorders

    Dec 1, 2023, 00:00

  • HTA48 Bridging the Gap: How to Align HTA and Health Care Decision Making in Switzerland

    Dec 1, 2023, 00:00

  • EPH141 The Impact of Short Bowel Syndrome in Adult Patients in Portugal

    Dec 1, 2023, 00:00

  • HTA306 The Combination Conundrum: Comparing Reimbursement Outcomes for Oncology Combination Products in the UK and France

    Dec 1, 2023, 00:00

  • EE135 Efficiency Management of Immunization Programs in Peru, in the Context of the COVID-19 Pandemic: The Fully Liquid Acellular Hexavalent Vaccine

    Dec 1, 2023, 00:00

  • RWD175 A Data Quality Framework to Assess Healthcare Data in Saudi Arabia: An Automated Approach

    Dec 1, 2023, 00:00

  • EPH156 Modelling Herpes Zosters Burden and Public Health Impact of Adjuvanted Recombinant Zoster Vaccine Among Adults Aged ≥50 Years Old in Seven Countries in Central and South America

    Dec 1, 2023, 00:00

  • HPR166 Access to Innovative Treatment Through Performance-Based Contracts in Fran Recommendations From Multidisciplinary Experts’ Workshops

    Dec 1, 2023, 00:00

  • EE699 Economic Burden of Propionic Acidemia by Age Stratum in the United States

    Dec 1, 2023, 00:00

  • MSR158 Successful Use of Propensity Score Methods for HTA in Germany: A Near-Impossible Task?

    Dec 1, 2023, 00:00

  • HTA241 Health Equity and the Health Technology Assessment Process: Are Children and Young People Being Overlooked? A Review of Pediatric National Institute of Health and Care Excellence Technology Appraisals

    Dec 1, 2023, 00:00

  • EE610 Opportunities to Improve the Cost Effectiveness of the Care Pathway in Acute Ischemic Stroke: A Decision Tree Analysis

    Dec 1, 2023, 00:00

  • EPH52 Survey of Situation and Severity of Public Problems Affecting Health in an Industrial District in Thailand

    Dec 1, 2023, 00:00

  • EE316 The Cost-Saving of the Introduction of Dapagliflozin in Algeria After Primary Failure of Oral Anti-Diabetics in Patients With Types 2 Diabetes (T2DM)

    Dec 1, 2023, 00:00

  • EE598 Cost-Utility of Influenza Vaccination for the Brazilian Elderly Population With a High Dose Quadrivalent Vaccine in the Public Healthcare Sector

    Dec 1, 2023, 00:00

  • HTA143 Drug Market Access Delays in Fran What Role May Cost-Effectiveness Evaluations Play in Varying These Timescales?

    Dec 1, 2023, 00:00

  • EE451 Methods to Measure the Environmental Impacts of Health Technologies and to Include Them in Economic Evaluations: A Scoping Literature Review

    Dec 1, 2023, 00:00

  • EPH204 Epidemiology and Patient Characteristics of Pemphigus Vulgaris in UK: A Retrospective Cohort Study Using Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES)

    Dec 1, 2023, 00:00

  • RWD26 Dupixam: An Algorithm to Identify Patients with Atopic Dermatitis Among Dupilumab-Treated Population Using the SNDS (SYSTEME NATIONAL DES DONNEES DE SANTE) in France

    Dec 1, 2023, 00:00

  • EE334 Five-Year Budget Impact of Community-Based HIV Testing Strategies for Oral Pre-Exposure Prophylaxis Scale-up in Western Kenya: A Modeling Analysis

    Dec 1, 2023, 00:00

  • EE84 Healthcare Resource Use and Cost in Metastatic Castration Resistant Prostate Cancer (mCRPC) in Finland

    Dec 1, 2023, 00:00

  • EE264 Cost-Effectiveness Analysis of Upadacitinib in Patients with Active Non-Radiographic Axial Spondyloarthritis in Greece

    Dec 1, 2023, 00:00

  • EE522 Cost-Effectiveness of Direct Oral Anticoagulants (DOACS) Versus Low-Molecular-Weight Heparins (LMWH) in Patients with Cancer-Associated Venous Thromboembolism (CAT) in Hong Kong

    Dec 1, 2023, 00:00

  • HPR81 Challenges in the Identification of Unmet Needs in Rare Diseases: Towards the Development of a Framework

    Dec 1, 2023, 00:00

  • MSR18 Modelling Challenges in Geographic Atrophy

    Dec 1, 2023, 00:00

  • HSD21 Regional Differences in the Use of Ige Testing in Primary Care: The Case of Sweden

    Dec 1, 2023, 00:00

  • MT50 Real-World Utilization and Outcomes of Transcatheter Mitral Valve Leaflet Repair (TMVLR) in Asian Patients with Mitral Regurgitation: A Singapore Experience

    Dec 1, 2023, 00:00

  • PCR2 Patients’ and Healthcare Professionals’ Preferences Regarding Lipid-Lowering Therapies for Patients with Very High Cardiovascular Risk and Established Atherosclerotic Cardiovascular Disease

    Dec 1, 2023, 00:00

  • HSD75 Optimizing Preoperative Assessment Through a Digital Healthcare Platform for Triage and Stratification in Joint Replacement Surgery: A Real-World Evaluation

    Dec 1, 2023, 00:00

  • EE701 Cost-Effectiveness Analysis of Polatuzumab Vedotin Combined with Chemoimmunotherapy in Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in China

    Dec 1, 2023, 00:00

  • PT33 Cost-Effectiveness of Pembrolizumab Plus Chemotherapy, With or Without Bevacizumab for the First-Line Treatment of PD-L1-Positive Patients With Persistent, Recurrent, or Metastatic Cervical Cancer in France

    Dec 1, 2023, 00:00

  • EE389 Collective vs Health Insurance Perspective in a French Efficiency Model: A Diversity of Cost Measurement Sources

    Dec 1, 2023, 00:00

  • P24 Improving Efficiency of Living Systematic Literature Reviews (SLR) with Artificial Intelligence (AI): Assisted Extraction of Population, Intervention/Comparator, Outcome, and Study Design (P-I/C-O-S)

    Dec 1, 2023, 00:00

  • SA48 Comparative Effectiveness Based on Win Ratios: Do Conventional ITC Approaches Work?

    Dec 1, 2023, 00:00

  • MSR75 Correlate: Assessing Dose Effect Using Targeted Maximum Likelihood Estimation (TMLE)

    Dec 1, 2023, 00:00

  • EE279 Model-Projected Long-Term Clinical Outcomes of Exagamglogene Autotemcel (exa-cel) Gene-Edited Therapy in Patients with Transfusion-Dependent Beta-Thalassemia in the United Kingdom

    Dec 1, 2023, 00:00

  • RWD27 Opportunities and Challenges in Linkage of Early Access Databases With the French National Claims Database: A RWE Effectiveness Study of AZD7442 for Pre-Exposure Prophylaxis Against COVID-19 in Immunocompromised Patients

    Dec 1, 2023, 00:00

  • CO131 Using Non-Randomized Trials to Assess the Clinical Benefit of Systemic Anti-Cancer Treatments: Viable or Not?

    Dec 1, 2023, 00:00

  • EPH20 Muscular Dystrophy-Related Hospitalizations and Outpatient Procedures in the Brazilian Public Healthcare System: A Real World Data Analysis

    Dec 1, 2023, 00:00

  • HTA110 Acceptability of Surrogate Endpoints by Health Technology Assessment Bodies: Results from a Systematic Review of Transparency Committee Assessments in France

    Dec 1, 2023, 00:00

  • EPH218 Knowledge of Contraception and Sexually Transmitted Diseases Regarding the Quality of Education and Parent-Child Relationship Among Secondary School Students

    Dec 1, 2023, 00:00

  • HTA52 Time to HTA Assessment Completion By HTA Agency Archetype: Five-Year Review for 20 European Countries

    Dec 1, 2023, 00:00

  • EE272 Cost-Effectiveness of Voclosporin in Combination with Mycophenolate Mofetil for Active Lupus Nephritis in Sweden

    Dec 1, 2023, 00:00

  • CO66 Improvements in the Peabody Developmental Motor Scale, Second Edition (PDMS-2) and Correlation With Bayley-III Scores and Motor Milestones in Aromatic L-Amino Acid Decarboxylase Deficiency (AADCd)

    Dec 1, 2023, 00:00

  • Clinical Outcomes

    Dec 1, 2023, 00:00

  • CO41 Long-Term Clinical Outcomes in People with Heart Failure with Preserved Ejection Fraction (HFpEF) Treated with Standard Care

    Dec 1, 2023, 00:00

  • MSR93 Hype, Not Hope: Using Bayesian Methods in Drug Development

    Dec 1, 2023, 00:00

  • HTA280 Pharmacoeconomic Research As an Area for Drugs Comparison

    Dec 1, 2023, 00:00

  • HPR79 Analysis of Newly FDA Approved Medicines and the Licensing Status By Titck in Turkiye

    Dec 1, 2023, 00:00

  • EPH113 Assessment of the Quality of Life in Patients With Acute Ischemic Stroke Diagnosed With Brainomix Artificial Intelligence-Based System, Under Different Therapeutic Approaches (Standard Treatment, Thrombolysis, Thrombectomy)

    Dec 1, 2023, 00:00

  • EE46 BoNT-As for Cervical Dystonia: Cost of Treatment and Response to Therapy in Canadian Patients

    Dec 1, 2023, 00:00

  • EE199 A Systematic Literature Review of Economic Evaluations of Community-Based Interventions to Improve Mobility, Continence, and Psychological Wellbeing in Individuals with Neuro-Physical Disabilities

    Dec 1, 2023, 00:00

  • RWD178 Real-World Evidence in Post-Authorization Studies: Review of European Databases in the ENCePP EU Pas Register® Between 2010 – 2023

    Dec 1, 2023, 00:00

  • EE547 The Societal Costs of Metachromatic Leukodystrophy (MLD) in the United States

    Dec 1, 2023, 00:00

  • HSD72 Improving Patient Care for Chronic Kidney Disease-Related Anemia in Italy: A Survey to Evaluate the Nephrological Card As a Tool for Optimizing Treatment Pathway

    Dec 1, 2023, 00:00

  • Medical Technologies

    Dec 1, 2023, 00:00

  • PT28 Lost in PICO? a Simulation of the EU HTA Scoping Process

    Dec 1, 2023, 00:00

  • PCR195 Patient Voice in Smc Technology Appraisals for Orphan and Ultra-Orphan Diseases

    Dec 1, 2023, 00:00

  • MT25 What Evidence Should Medical Technology Companies Expect HTA Bodies to Review?

    Dec 1, 2023, 00:00

  • HTA192 What Must Change if Future Evidence Pricing and Access Challenges Are to Be Successfully Overcome?

    Dec 1, 2023, 00:00

  • EPH40 Evolving Impact of the COVID-19 Pandemic in Chronic Dialysis Recipients According to Wave Sub-Periods

    Dec 1, 2023, 00:00

  • EE738 Cost-Effectiveness of Renal Denervation for Uncontrolled Hypertension: An Analysis for Sweden Based on the SPYRAL HTN-ON MED Trial and Other Contemporary Evidence

    Dec 1, 2023, 00:00

  • EE177 Cost-Effectiveness Modelling in Moderate to Severe Ulcerative Colitis: Novel Approaches to Capture Variable Induction Periods, Treatment Sequences, and Variable Treatment Cycle Lengths

    Dec 1, 2023, 00:00

  • HTA133 The Number of NICE Appraisal Terminations Is Increasing, and Products With Multiple Indications Are Disproportionally Impacted

    Dec 1, 2023, 00:00

  • EE519 Do We Need Three-State Decision Analytic Models in Metastatic Oncology? An Alternative Approach to Estimate Quality Adjusted Life Years (QALY)

    Dec 1, 2023, 00:00

  • EPH182 Factors Associated with Augmentation Agent Use in Patients with Treatment-Resistant Depression

    Dec 1, 2023, 00:00

  • HSD14 X-Linked Retinitis Pigmentosa Impacts Patients’ Independence, Work Status, and Quality of Life: Insights from the Cross-Sectional Explore Xlrp-1.2 Physician Survey

    Dec 1, 2023, 00:00

  • EE483 A Cost-Impact Analysis of a Novel Diagnostic Test to Assess Community-Acquired Pneumonia Etiology in the Emergency Departments: A French Perspective

    Dec 1, 2023, 00:00

  • HPR11 Oncolytic Therapies in China: Laying the Groundwork for a Successful Launch

    Dec 1, 2023, 00:00

  • MSR95 Simulated Treatment Comparison or Matching-Adjusted Indirect Comparison: Which Wins in the Battle for Prominence and Validity in Population-Adjusted Indirect Treatment Comparison?

    Dec 1, 2023, 00:00

  • EE596 Cost-Effectiveness and Public Health Impact of a Nine-Valent Human Papillomavirus Vaccination Program in Ukraine

    Dec 1, 2023, 00:00

  • MT62 Virtual Reality Training on Medical Devices: A Proof of Concept Study

    Dec 1, 2023, 00:00

  • HSD34 Real-World Usage of Biologic Disease-Modifying Anti-Rheumatic Drugs in Patients with Axial Spondyloarthritis in Germany

    Dec 1, 2023, 00:00

  • SA55 Whole-Body MRI Accuracy and Cost-Effectiveness Compared with Standard Pathways for Detecting and Monitoring Bone Metastases in Prostate Cancer: A Systematic Review

    Dec 1, 2023, 00:00

  • EE664 Total Direct Costs of Ovarian Cancer in Colombia: A National Cohort Study Based on Administrative Claims Databases

    Dec 1, 2023, 00:00

  • MSR121 Use of External Control Arms in Pharmaceutical Submissions to the National Institute for Health and Care Excellence for Technology Appraisals: A Targeted Review

    Dec 1, 2023, 00:00

  • HTA112 The NICE Medical Technologies Evaluation Program: An Analysis of Clinical and Economic Evidence Evaluated in Published Medical Technology Guidance

    Dec 1, 2023, 00:00

  • EPH48 Targeted Influenza Vaccination in at Risk Populations – How Avoided Cases Translate into Clinical and Economic Benefits for Czech Republic, Hungary, and Romania

    Dec 1, 2023, 00:00

  • HTA364 Can Artificial Intelligence and Machine Learning Be Used to Demonstrate the Value of a Technology for HTA Decision-Making?

    Dec 1, 2023, 00:00

  • EE253 Comparative Efficacy of Beclomethasone/Formoterol/Glycopyrronium (BDP/FOR/GLY) Vs Budesonide/Glycopyrrolate/Formoterol (BUD/GLY/FOR): Indirect Comparison in Chinese Patients with Chronic Obstructive Pulmonary Disease

    Dec 1, 2023, 00:00

  • HTA138 Impact of Publication of the French Commission for Economic and Public Health Evaluation (CEESP) Doctrine on French Medico-Economic Evaluation – a Quantitatve Analysis

    Dec 1, 2023, 00:00

  • CO90 Augmenting Synthetic Control Arms Using Bayesian Borrowing: A Case Study in First-Line Non-Small Cell Lung Cancer

    Dec 1, 2023, 00:00

  • CO136 Systematic Literature Review (SLR) of Clinical Data in Third-Line and Beyond (3L+) Small Cell Lung Cancer (SCLC) Patients

    Dec 1, 2023, 00:00

  • EE166 Healthcare Resource Use and Economic Burden of Stroke Among People with Type 2 Diabetes: A Real-World Evidence Study in France

    Dec 1, 2023, 00:00

  • HTA57 Costing for Health Economics Evaluation: The Case of the Brazilian Universal Health System

    Dec 1, 2023, 00:00

  • RWD165 Improving Evidence Generation From Rare Disease Registries: Performing Variable Gap Analyses

    Dec 1, 2023, 00:00

  • HTA348 How to Align EU HTA with National Market Access?

    Dec 1, 2023, 00:00

  • PCR194 A Global Perspective on Self-Reported Productivity Losses Associated With Osteogenesis Imperfecta

    Dec 1, 2023, 00:00

  • EE381 Health Benefits and Cost-Effectiveness Analysis of Early Breast Cancer Diagnosis in Bulgaria

    Dec 1, 2023, 00:00

  • EE100 Costs of Home Mechanical Ventilation and Oxygen Therapy in Russia: Real-World Data

    Dec 1, 2023, 00:00

  • HPR171 WTP Threshold: A Review of International Approaches and Inspiration for Cultivation of Current Situation in the Czech Republic

    Dec 1, 2023, 00:00

  • RWD126 Assessment of Cutaneous Malignant Melanoma Knowledge, Tanning Attitude, and Sun-Protective Behavior in Gree A Significant Gap in the National Preventive Health Strategy

    Dec 1, 2023, 00:00

  • OP24 Collaborating for Better Outcomes: How Can Value-Based Partnerships Unlock Value Across Stakeholder Groups and Elevate Pharma's Role Within Healthcare Ecosystems?

    Dec 1, 2023, 00:00

  • MSR159 A Novel Unanchored Simulated Treatment Comparison Approach for Time-to-Event Data

    Dec 1, 2023, 00:00

  • EPH240 Epidemiology, Economic Burden, and Humanistic Burden in Multiple Sclerosis Spasticity (MSS): A Systematic Literature Review (SLR)

    Dec 1, 2023, 00:00

  • EE186 A Comparative Cost Analysis between Dalbavancin, Oritavancin and Delafloxacin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Spain

    Dec 1, 2023, 00:00

  • CO11 Medication Adherence in Osteoporosis Treatments and the Impact in Patients' Quality of Life

    Dec 1, 2023, 00:00

  • EE51 Rethinking Economic Evaluation in Amyotrophic Lateral Sclerosis Treatment: Embracing Alternative Model Conceptualizations

    Dec 1, 2023, 00:00

  • HPR76 Financial Feasibility Study of Incremental Modified Drugs Development by Domestic Pharmaceutical Industry

    Dec 1, 2023, 00:00

  • EPH157 Developing an Analysis to Determine the Value of Time When Delaying the Who's Seasonal Influenza Vaccine Strain Selection Recommendation

    Dec 1, 2023, 00:00

  • HTA149 Handling Uncertainty in Health-Economic Assessments: Experience From COVID-19 in France

    Dec 1, 2023, 00:00

  • EPH223 Clinical, Economic, and Humanistic Burden of Atherosclerotic Cardiovascular Disease (ASCVD) and Familial Hypercholesterolemia (FH) in Latin America: A Scoping Review (SR)

    Dec 1, 2023, 00:00

  • RWD141 How Global Datasets Can Shed Light on Health Inequalities: An Environmental Scan of Publicly Available Sources

    Dec 1, 2023, 00:00

  • EE82 A Cost-Utility Analysis of the MyPal eHealth Application, an ePro Intervention Aiming to Foster Palliative Care of Cancer Patients: Results From a Randomized Clinical Trial in 4 European Countries

    Dec 1, 2023, 00:00

  • EE322 A Cost Analysis for Macrovascular Events, Comparison of Glargine 300U/Ml (GLA-300) and Degludec 100U/Ml (IDeg-100) in the Treatment of Type 2 Diabetes Mellitus in Older Population or Renal Impairment Individuals in Latin America

    Dec 1, 2023, 00:00

  • HSD120 Tafamidis in the Treatment of Transthyretin Amyloid Cardiomyopathy in Poland: Epidemiological Data and Demographic Data from an Expanded Access Program

    Dec 1, 2023, 00:00

  • RWD54 Real-World Evidence for Patient Outcomes and Mutational Burden in Non-Small Cell Lung (NSCLC) Cancer Patients in England Using EGFR Biomarker Test Data from Routine Clinical Care

    Dec 1, 2023, 00:00

  • EE361 From Biobank Sample to Breast Cancer Prevention—Cost-Effectiveness Analysis of Returning Genomic Data to Sample Donors

    Dec 1, 2023, 00:00

  • EE548 Data Availability and Modelling Approaches in Health Economic Evaluation of Cystic Fibrosis: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • HPR49 Clinical Rationales Support Access to Novel Combination Therapies in Oncology: Are We Trying to Play a New Game with the Old Rules?

    Dec 1, 2023, 00:00

  • EE136 The Socio-Economic Value of Adult Immunization: Results from a Comprehensive Literature Review of Four Immunization Programs in Ten Countries

    Dec 1, 2023, 00:00

  • RWD96 Burden of Chronic Obstructive Pulmonary Disease (COPD) Patients Uncontrolled Despite Triple-Therapy in France

    Dec 1, 2023, 00:00

  • HTA248 Incorporating Patient Perspectives in HTA Assessments for Rare Diseases: Insights From Multiple HTA Assessments

    Dec 1, 2023, 00:00

  • HTA310 Evolution of French Economic Opinions Published By the Economic Evaluation and Public Health (CEESP) in Oncology

    Dec 1, 2023, 00:00

  • EE338 Economic Impact of Herpes Zoster and Postherpetic Neuralgia on Healthcare Resource Use in Sweden

    Dec 1, 2023, 00:00

  • EPH4 Burden of Disease and Cost of Permanent Productivity Loss of Cardiovascular Disease (CVD) in South America (SA)

    Dec 1, 2023, 00:00

  • PCR14 Prioritization of Social Disability Management Using a Patient Reported Outcome Questionnaire in Patients Suffering from Multiple Sclerosis (MS)

    Dec 1, 2023, 00:00

  • HTA157 Reflection on Medicines That Have Recently Come Off Patent and Have Been Rejected by NICE in the Past 20 Years: A Case Study of Abiraterone for Treating Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer (MHSPC)

    Dec 1, 2023, 00:00

  • HSD82 Impact of the COVID-19 Pandemic in the Netherlands on Primary Healthcare Use and Clinical Outcomes in People with Type 2 Diabetes

    Dec 1, 2023, 00:00

  • EPH89 Epidemiological Disease Burden of Female Infertility, N.O.S, Based on Routinely Collected Health Insurance Claims Data Between 2010-2019

    Dec 1, 2023, 00:00

  • EE463 Economic Evaluation of Single Pill Combination Clopidogrel: Aspirin Versus Free Combination Clopidogrel Plus Aspirin for Prevention of Cardiovascular Events After Acute Coronary Syndrome in China

    Dec 1, 2023, 00:00

  • CO67 Development of an Investigator Global Assessment of Severity in Propionic Acidemia

    Dec 1, 2023, 00:00

  • CO15 Clinical Outcomes of Patients with Relapsed/Refractory Large B-Cell Lymphoma Receiving Second-Line Therapy in England: A Multicenter, Retrospective, Real-World Study

    Dec 1, 2023, 00:00

  • PCR65 Assessment of the EQ-5D and DMD-QoL for Duchenne Muscular Dystrophy: A Patient and Caregiver Study

    Dec 1, 2023, 00:00

  • HTA268 Key Issues in the Methods and Process of Health Technology Assessment in China: A National Expert Survey

    Dec 1, 2023, 00:00

  • HTA111 Population, Intervention, Comparator, Outcomes (PICO) of ATMPs and Potential Impact on the Upcoming EU Regulation on HTA

    Dec 1, 2023, 00:00

  • HTA329 The Race to Improve Health Technology Assessment of Gene Therapies: Which Countries Are Embracing Recommendations?

    Dec 1, 2023, 00:00

  • EE265 Cost-Effectiveness of Efmoroctocog Alfa in Treatment of Severe Hemophilia A Patients in Turkey

    Dec 1, 2023, 00:00

  • EE173 Budget Impact Analysis of IDegAsp for the Management of Type 2 Diabetes in Saudi Arabia

    Dec 1, 2023, 00:00

  • HSD128 Preferences of Healthcare Providers in Switzerland for Attributes of Pediatric Hexavalent Vaccines

    Dec 1, 2023, 00:00

  • Health Policy Regulatory

    Dec 1, 2023, 00:00

  • PCR127 Needs and Experiences of Patients and Healthcare Professionals Towards Shared Decision Making in Multiple Myeloma Clinical Practi A Qualitative Study in Europe

    Dec 1, 2023, 00:00

  • MSR101 Methodological Insights on Indirect Treatment Comparisons for Ulcerative Colitis Therapies in NICE Submissions

    Dec 1, 2023, 00:00

  • HTA319 3-Year Report Card: RWE Collection in Germany

    Dec 1, 2023, 00:00

  • EE659 Estimating the Economic Consequences of Migraine in Sweden: A Fiscal Model Using the Government Perspective of Costs

    Dec 1, 2023, 00:00

  • EPH272 It Is Known Since 1922 at 2B Level of Evidence, Yet Not Used: Attitude Towards Intraosseous Medication

    Dec 1, 2023, 00:00

  • RWD124 Characteristics of Patients with Advanced Endometrial Cancer Who Received Pembrolizumab As Part of an Early Access Program (EAP) in Accordance with KN-775 Labelling

    Dec 1, 2023, 00:00

  • HTA324 Recent Landscape of Drug Re-Assessments by G-BA – What Is the Impact of New Evidence on the Benefit Assessment Outcome?

    Dec 1, 2023, 00:00

  • PCR250 Management of Osteogenesis Imperfecta: Self-Reported Funding Sources for Healthcare, Consumables and Services Across the EU5 and Nordics

    Dec 1, 2023, 00:00

  • HTA361 Living Systematic Review (LSR) in Health Technology Assessment (HTA): Current Guidance, Methods, and Challenges

    Dec 1, 2023, 00:00

  • PCR63 Health-Related Quality of Life in COVID-19: A Vignette Study

    Dec 1, 2023, 00:00

  • RWD117 Comparison the Annual, Nationwide Health Insurance Treatment Cost of Hip Osteoarthritis Based on Routinely Collected Financing Data in 2010 and 2018 in Hungary

    Dec 1, 2023, 00:00

  • An Updated Review of Food and Drug Administration Warning and Untitled Letters for Clinical Outcome Assessment Claims Between 2013 and 2021

    Dec 1, 2023, 00:00

  • HSD89 The Operational Effectiveness of Using an M L-Driven Patient Medical Record: A Simulated Comparative Study Using Real-World Data

    Dec 1, 2023, 00:00

  • HTA316 Understanding the Application of Various Statistical Analysis Methods to Inform Comparative Effectiveness of Ultra Orphan Treatments: A Review of NICE HST Guidance

    Dec 1, 2023, 00:00

  • CO156 Direct Oral Anticoagulants in Adults with Non-Valvular Atrial Fibrillation: Systematic Review and Network Meta-Analysis of Real-World Evidence

    Dec 1, 2023, 00:00

  • HTA159 Review of Survival Modeling Approaches Adopted in NICE Technology Appraisals (TAs) in Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2023, 00:00

  • PCR98 Reduced Dialysis Adherence and Greater Medication Use Associated with Increased Itch Severity

    Dec 1, 2023, 00:00

  • OP13 Impact of Pay-for-Performance Programs on Diabetes Management: A Critical Analysis

    Dec 1, 2023, 00:00

  • EE14 Cost Effectiveness of Sensor Augmented Pump Therapy with Automated Insulin Suspension in the Management of Type 1 Diabetes (T1D) in Bulgaria

    Dec 1, 2023, 00:00

  • EE426 The Acceptance of Indirect Treatment Comparisons in Pharmacoeconomic Analyses by the Dutch Healthcare Institute (ZIN)

    Dec 1, 2023, 00:00

  • EE712 Budget Impact Analysis of Faricimab for Treating Patients With Diabetes Macular Edema or Neovascular Age-Related Macular Degeneration in El Salvador, Honduras, and Dominican Republic

    Dec 1, 2023, 00:00

  • EE305 Cost-Effectiveness Analysis of Genetic Screening in First-Degree Relative of Hypertrophic Cardiomyopathy Patients From the Perspective of the Brazilian United Health System

    Dec 1, 2023, 00:00

  • CO126 Effectiveness of Cell-Based Treatment Compared to Current Standard of Care for Knee Osteoarthritis Patients in the Netherlands

    Dec 1, 2023, 00:00

  • HSD42 The Humanistic Impact of X-Linked Retinitis Pigmentosa (XLRP): Results from the Explore Xlrp-2 Retrospective Chart Review and Cross-Sectional Survey of Patients and Caregivers in 10 Countries

    Dec 1, 2023, 00:00

  • MSR140 Current Trends in Survival Extrapolation Methods: A Review of NICE Health Technology Appraisals for Oncology Drugs

    Dec 1, 2023, 00:00

  • HTA240 An Evaluation of the Reimbursement Status of CAR-T Cell Therapies in the EU-4 and UK

    Dec 1, 2023, 00:00

  • EPH268 Effectiveness of Pneumococcal Vaccination in Older Adults in a Real-World Setting: A Systematic Review and Meta-Analysis of Observational Studies Using Test-Negative Designs

    Dec 1, 2023, 00:00

  • Health Technology Assessment

    Dec 1, 2023, 00:00

  • SA23 Bruton Tyrosine Kinase Inhibitor (BTKi) Monotherapy for the Treatment of ‘High-Risk’ Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): A Systematic Literature Review (SLR)

    Dec 1, 2023, 00:00

  • EE245 Indirect Cost of Spinal Muscular Atrophy (SMA) in Singapore

    Dec 1, 2023, 00:00

  • EE702 Humanistic and Economic Burden of Methylmalonic Acidemia—A Systematic Literature Review

    Dec 1, 2023, 00:00

  • EE622 Improved Glycemic Outcomes and Associated Cost Savings with an Advanced Hybrid Closed Loop System for People with Type 1 Diabetes with Suboptimal Glycemic Control in Europe

    Dec 1, 2023, 00:00

  • EPH76 Triptan Switches for Danish Migraine Patients Treated With at Least Three Distinct Triptans Before Discontinuation—A Register Based Study

    Dec 1, 2023, 00:00

  • CO96 Myelofibrosis Symptom Assessment Form Total Symptom Score (MFSAF TSS) v4.0: Measurement Properties from the Momentum Phase 3 Study

    Dec 1, 2023, 00:00

  • Preferences for Palliative and End-of-Life Care: A Systematic Review of Discrete Choice Experiments [Editor's Choice]

    Dec 1, 2023, 00:00

  • EE677 Cost-Consequence of Using NGS vs Single-Testing in NSCLC Patients at Diagnosis – Real-World Data From a Portuguese Hospital

    Dec 1, 2023, 00:00

  • MSR112 Assessing the Feasibility of Applying Natural Language Processing for Systematic Literature Reviews: A Case Study in Non-Small-Cell Lung Cancer

    Dec 1, 2023, 00:00

  • EE121 Cost-Efficiency and the Opportunity for Expanded Treatment Access with Incremental Increases in Biosimilar Adalimumab and Tocilizumab Use: A European Perspective

    Dec 1, 2023, 00:00

  • EE718 Cost-Effectiveness of Medical Cannabis for Treatment of Chronic Pain: A Longitudinal Cohort Study of a Large German Hybrid Telemedicine Platform

    Dec 1, 2023, 00:00

  • EE689 A Cost-Effectiveness Analysis of Atezolizumab as Adjuvant Treatment (Monotherapy) for Adult Patients With Non-Small Cell Lung Cancer Following Resection and Platinum-Based Chemotherapy in Greece

    Dec 1, 2023, 00:00

  • HSD41 Healthcare Models for Rare Diseases: A Systematic Literature Review for the Development of a Comprehensive Model in a Latin American Country

    Dec 1, 2023, 00:00

  • EE602 Examination of Changes Experienced in Prices of Goods and Services That Affect Manufacturing Costs in Health Industry for Slovenia

    Dec 1, 2023, 00:00

  • PCR137 Understanding the Signs, Symptoms and Impacts of Metachromatic Leukodystrophy (MLD)

    Dec 1, 2023, 00:00

  • SA54 Quality of Life, Economic Burden, and Comorbidities Associated with Essential Tremor: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • HPR129 Catastrophic Health Expenditure: A Comparative Analysis of in Elderly Household and Non-Elderly Household in Korea

    Dec 1, 2023, 00:00

  • EE731 Estimating the Economic Impact of Enabling the Digital Transfer of Patients’ Prescription Information in the English National Health Service

    Dec 1, 2023, 00:00

  • EPH199 Factors Associated With Hospitalization for E-Cigarette/Vaping Associated Lung Injury (EVALI) in the United States

    Dec 1, 2023, 00:00

  • EE362 A Budget Impact Analysis of Pertuzumab, Trastuzumab, and Chemotherapy in the Neoadjuvant Setting for HER2-Positive High-Risk Early Breast Cancer Patients: Insights from the Tuscany Regional Health Care System Perspective

    Dec 1, 2023, 00:00

  • HPR24 Utilisation and Expenditure on Blood Glucose Test Strips in Ireland—The Impact of Health Technology Management in Reducing and Containing Expenditure

    Dec 1, 2023, 00:00

  • EE394 Understanding Reasons of Negative Reimbursement Decisions for Orphan Drugs in the Spanish National Health System (APRIL 2019-MAY 2023)

    Dec 1, 2023, 00:00

  • EE494 Optimizing Treatment of Schizophrenia: Pharmacoeconomic Consequences and Potential for Patient Switching to Long-Acting Injectables

    Dec 1, 2023, 00:00

  • RWD112 Factors Associated with High Costs of Patients with Non-Alcoholic Fatty Liver Disease: An Observational Study Using the French Constances Cohort

    Dec 1, 2023, 00:00

  • CO91 Association Between Progression-Free Survival (PFS) and Overall Survival (OS) in Patients with Relapsed/Refractory (RR) Multiple Myeloma (MM)

    Dec 1, 2023, 00:00

  • RWD135 A Demographic Description of Women With Uncomplicated Urinary Tract Infection in England: A Primary Care Electronic Health Records and Notes Review

    Dec 1, 2023, 00:00

  • EE536 Cost-Effectiveness of Axicabtagene Ciloleucel (axi-cel) Vs Standard of Care for Adult Patients with Relapsed or Refractory Follicular Lymphoma as 4TH or Later Line Treatment in Sweden

    Dec 1, 2023, 00:00

  • EE58 Endometrial Cancer Care in Colombia: A Cost-of-Illness Study Based on Administrative Claims Databases

    Dec 1, 2023, 00:00

  • PCR174 The Patient-Centered Core Impact Set Taxonomy: A Practical Example of Use and Refinement Using Voice-of-the-Patient Reports and Patient Interviews

    Dec 1, 2023, 00:00

  • MT8 Assessing Feasibility of Socially Assistive Humanoid Robots in Assisting in Nursing Routine

    Dec 1, 2023, 00:00

  • EE436 Economic Evaluation of Transcatheter Versus Surgical Aortic Valve Replacement in Low- and Intermediate-Risk Patients with Severe Aortic Stenosis in China

    Dec 1, 2023, 00:00

  • EE306 Utilizing Real World Evidence for Cost-Effectiveness Analysis of the Disease Management Program for Chronic Heart Failure Herzmobil Tirol

    Dec 1, 2023, 00:00
  • «
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26 (current)
  • 27
  • 28
  • 29
  • 30
  • »